News BeiGene, Ltd.

Equities

BGNE

US07725L1026

Real-time Estimate Cboe BZX Other stock markets 12:19:24 2024-04-23 pm EDT			5-day change	1st Jan Change
139.2 ^USD	+6.28%		+3.62%	-22.99%

05:20pm	BeiGene Says Tislelizumab Gets European Commission's Approval to Treat Non-Small Cell Lung Cancer; Shares Rise	MT
04:59pm	BeiGene Shares Rise 7% After European Approval of Tislelizumab Cancer Treatment	DJ

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

BeiGene Says Tislelizumab Gets European Commission's Approval to Treat Non-Small Cell Lung Cancer; Shares Rise	11:20am	MT
BeiGene Shares Rise 7% After European Approval of Tislelizumab Cancer Treatment	10:59am	DJ
Technology Stocks Lead Asian Equities Traded in the US as American Depositary Receipts Higher in Tuesday Trading	10:38am	MT
BeiGene Says Tislelizumab Gets European Commission's Approval to Treat Non-Small Cell Lung Cancer	09:20am	MT
BeiGene Receives European Commission Approval for Tislelizumab as Treatment for Non-Small Cell Lung Cancer	06:04am	BU
BeiGene, Ltd. Receives European Commission Approval for Tislelizumab as Treatment for Non-Small Cell Lung Cancer	06:00am	CI
BeiGene to Award Shares Worth $15 Million to 11 Directors	Apr. 17	MT
Western Drugmakers Seeking Alternative Suppliers as US Looks to Restrict Chinese Biotech	Apr. 11	MT
Western Drugmakers Seeking Alternative Suppliers as US Looks to Restrict Chinese Biotech	Apr. 11	MT
BeiGene Opens New Factory in Guangzhou for Antibody-Drug Conjugates	Apr. 10	MT
Beigene Shrinks Loss by 56% in 2023	Mar. 29	MT
Bernstein Adjusts BeiGene's Price Target to $161 From $196, Maintains Market Perform Rating	Mar. 27	MT
Tech Stocks Lead Asian Equities Traded in the US as American Depositary Receipts Slightly Lower in Friday Trading	Mar. 22	MT
BeiGene, Ltd. Announces Executive Changes	Mar. 20	CI
BeiGene Receives FDA Approval for TEVIMBRA for the Treatment of Advanced or Metastatic Esophageal Squamous Cell Carcinoma after Prior Chemotherapy	Mar. 15	AQ
Beigene's Esophageal Cancer Drug Gets US FDA Nod	Mar. 15	MT
Beigene Insider Sold Shares Worth $8,368,017, According to a Recent SEC Filing	Mar. 14	MT
BeiGene Says FDA Approves Tevimbra to Treat Some Esophageal Cancer Patients	Mar. 14	DJ
BeiGene Gets FDA Approval for Esophageal Cancer Treatment	Mar. 14	MT
BeiGene Receives FDA Approval for TEVIMBRA® for the Treatment of Advanced or Metastatic Esophageal Squamous Cell Carcinoma After Prior Chemotherapy	Mar. 14	BU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News BeiGene, Ltd.

Equities

BGNE

US07725L1026

Summary

Filters